Incyte

DelveInsight's 'Janus Kinase (JAK) Inhibitors Pipeline Insight, 2024' report details the global pipeline, including clinical trials, therapies, MOA, ROA, and key companies like Pfizer, Incyte Corporation, and AbbVie. It highlights emerging therapies like SDC-1801 and Povorcitinib, recent approvals such as upadacitinib for nr-axSpA, and ongoing Phase III trials like Incyte's povorcitinib for hidradenitis suppurativa.

Sun Pharma shares fell 5% after a US Court blocked Leqselvi launch, prohibiting it until a favorable court decision or patent expiry. Leqselvi treats severe alopecia areata. UBS and JPMorgan suggest potential settlements and future growth despite the injunction.

Sun Pharma's shares dropped 5% after a US court delayed the launch of its alopecia drug, Leqselvi, due to an injunction by Incyte Corp. Sun Pharma plans to appeal, while Nomura and Citi maintain 'neutral' and 'buy' ratings, respectively, on the stock. The delay could impact near-term earnings by 3-6% and affect competitive positioning.

U.S. District Court of New Jersey granted preliminary injunction delaying Sun Pharma's LEQSELVI launch due to patent infringement lawsuit by Incyte Corporation; Sun Pharma plans to appeal.

Merus N.V. reports financial results for Q3 2024, highlighting ongoing phase III trials for pétosemtamab in head and neck cancer treatment, with interim clinical data selected for presentation at ESMO® Asia 2024. The company's cash, equivalents, and marketable securities are expected to fund operations until 2028.

Regeneron Pharmaceuticals' PE, PB, and PS ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.

AbbVie's P/E ratio of 63.7 is 1.1x the industry norm, suggesting higher valuation. Its P/B ratio of 49.63 is 7.93x the average, indicating potential overvaluation. With a P/S ratio of 6.14, it's undervalued relative to sales. AbbVie's ROE of 18.4% is 14.39% above the industry average, showing efficient profit generation. EBITDA of $5.0B and gross profit of $10.26B are 5.21x and 5.03x the industry average, respectively, highlighting strong profitability. However, revenue growth of 4.31% is significantly lower than the industry average of 31.36%, suggesting potential sales decline.

Regeneron Pharmaceuticals' PE, PB, and PS ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability. However, low revenue growth raises concerns about market expansion.

Pelabresib combined with ruxolitinib significantly reduced splenomegaly and improved anemia in JAKi-naïve myelofibrosis patients, according to the phase 3 MANIFEST-2 trial. The combination therapy showed substantial spleen volume reduction, symptom relief, and anemia management, with manageable adverse effects.

Global LAG-3 Inhibitors Market expected to exceed USD 3 billion by 2029; Opdualag, first LAG-3 therapy, approved for melanoma. LAG-3 inhibitors show potential in combination therapies for various cancers and diseases. Key players include Bristol Myers Squibb, Roche, and Regeneron. Market valued at USD 625 million in 2023, projected to grow significantly.